Ascendis Pharma A/S
DKFinancials
Valuation Metrics
Ascendis Pharma A/S's Market Cap is $15.38B. At end of 2025 it was $9.49B. Ranked #692 of 3,118 in US market (top 22%), #216 of 1,474 on NASDAQ (top 15%), #32 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 12%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $15.38B | US#692/3,118 Sec#32/265 |
| Revenue | $1.19B | US#1,764/3,118 Sec#48/265 |
| Net Income | $854M | US#605/3,118 Sec#21/265 |
| Total Assets | $2.68B | US#1,885/3,118 Sec#49/265 |
| Net Assets | $1.69B | US#1,366/3,118 Sec#43/265 |
| Employees | 1,189 | US#1,928/3,118 Sec#52/265 |
| Value | ||
| P/E | 18.01x | US#994/3,118 Sec#30/265 |
| P/B | 9.12x | US#2,585/3,118 Sec#189/265 |
| P/S | 12.91x | US#2,774/3,118 Sec#127/265 |
| EV/EBITDA | 169.44x | US#2,462/3,118 Sec#82/265 |
| FCF Yield | 2.47% | US#1,939/3,118 Sec#64/265 |
| Profitability | ||
| ROE | 50.63% | US#112/3,118 Sec#10/265 |
| ROA | 31.81% | US#32/3,118 Sec#8/265 |
| Op. Margin | 10.38% | US#1,543/3,118 Sec#62/265 |
| Revenue Growth | 130.35% | US#74/3,118 Sec#27/265 |
| Financial Health | ||
| Debt Ratio | 59.14% | US#663/3,118 Sec#143/265 |
| Total Debt | $528M | US#1,834/3,118 Sec#62/265 |
| FCF | $381M | US#1,022/3,118 Sec#35/265 |
| Cash | $954M | US#712/3,118 Sec#33/265 |
| Current Ratio | 2.99x | US#785/3,118 Sec#191/265 |
| Net Debt/EBITDA | -4.82x | US#76/3,118 Sec#3/265 |
| Performance | ||
| 1Y Return | 23.50% | US#1,043/3,118 Sec#101/265 |
| 1M Return | 9.26% | US#772/3,118 Sec#50/265 |
| From 52W High | -11.76% | US#868/3,118 Sec#50/265 |
| 1Y MDD | -19.66% | US#604/3,118 Sec#19/265 |
| Trading | ||
| Volume | 473,187 shares | US#2,329/3,118 Sec#221/265 |
| Trading Value | $118M | US#979/3,118 Sec#56/265 |
| Per Share | ||
| EPS | $13.82 | US#174/3,118 Sec#8/265 |
| BPS | $27.30 | US#968/3,118 Sec#19/265 |
Company Info
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.